Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Increases By 40.6%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 68,200 shares, an increase of 40.6% from the March 15th total of 48,500 shares. Approximately 3.1% of the company’s shares are sold short. Based on an average daily trading volume, of 827,000 shares, the short-interest ratio is presently 0.1 days.

Galmed Pharmaceuticals Stock Performance

GLMD stock opened at $1.38 on Friday. The firm has a 50 day simple moving average of $1.90 and a 200 day simple moving average of $2.73. Galmed Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $23.80. The stock has a market cap of $2.28 million, a P/E ratio of -0.08 and a beta of 0.70.

Analyst Upgrades and Downgrades

GLMD has been the topic of several analyst reports. Maxim Group reissued a “hold” rating on shares of Galmed Pharmaceuticals in a research report on Friday, April 4th. StockNews.com started coverage on Galmed Pharmaceuticals in a research report on Sunday, April 13th. They issued a “sell” rating for the company.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is currently owned by institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.